Identification of MaTu-MX Agent as a New Strain of Lymphocytic Choriomeningitis Virus (LCMV) and Serological Indication of Horizontal Spread of LCMV in Human Population  by Reiserová, Lucia et al.
t
c
m
t
o
t
c
b
l
s
(
c
n
v
m
t
a
t
S
m
t
u
d
Virology 257, 73–83 (1999)
Article ID viro.1999.9638, available online at http://www.idealibrary.com onIdentification of MaTu-MX Agent as a New Strain of Lymphocytic Choriomeningitis Virus
(LCMV) and Serological Indication of Horizontal Spread of LCMV in Human Population
Lucia Reiserova´,* Milota Kaluzova´,* Sˇtefan Kaluz,* Antony C. Willis,† Jan Za´vada,‡ Eva Za´vodska´,*
Zuzana Za´vadova´,‡ Fedor Cˇiampor,* Jaromı´r Pastorek,* and Silvia Pastorekova´*,1
*Institute of Virology, Slovak Academy of Sciences, Du´bravska´ cesta 9, 842 46 Bratislava, Slovak Republic, †MRC Immunochemistry Unit,
Department of Biochemistry, University of Oxford, Oxford, United Kingdom; and ‡Institute of Molecular Genetics,
Czech Academy of Sciences, Prague, Czech Republic
Received August 1, 1998; returned to author for revision October 19, 1998; accepted February 2, 1999
In this study we elucidated the molecular character of MaTu-MX, previously described as an unusual transmissible agent.
Amino acid sequencing of peptides generated from a 58-kDa MX-related protein purified from MaTu human carcinoma cells
allowed us to identify it as a nucleoprotein (NP) of lymphocytic choriomeningitis virus (LCMV). Northern blot analysis detected
LCMV-specific RNAs in MaTu cells. Comparative immunoprecipitations showed cross-reactivity between NP of LCMV strain
WE and MX NP. Using RT-PCR, we have cloned MX NP cDNA. According to sequence comparison, MX LCMV is as closely
related to both LCMV strains WE and Armstrong as these strains are to one another. Based on this finding we propose that
MX is a new strain of LCMV. We also showed that the stability of MX NP in MaTu cells is very high and that the virus is
transmissible by cell-to-cell contact or by cell-free extract to human HeLa and monkey Vero cells, but not to human AGS,
canine MDCK, mouse NIH 3T3, and hamster CHO cells. Finally, employing MX LCMV NP in immunoprecipitation and
solid-phase radioimmunoassay, we found 37.5% prevalence of anti-LCMV antibodies in human sera, suggesting possible
horizontal spread of the virus in the human population. © 1999 Academic Press
m
p
m
i
i
i
l
t
c
a
P
c
c
s
l
B
i
g
(
v
e
a
a
D
(Lymphocytic choriomeningitis virus (LCMV) is a proto-
ypic member of the Arenaviridae family that comprises
linically important human pathogens. It has gained
uch scientific attention as an experimental model for
he study of acute and persistent infections and the role
f the immune system in viral pathogenesis. Investiga-
ion of LCMV led to the establishment of several basic
oncepts in modern virology and immunology (reviewed
y Welsh, 1995; Peters et al., 1996).
Arenaviruses utilize a unique ambisense strategy of rep-
ication (Southern, 1996). Their genome consists of two
ingle-stranded RNA segments designated S (small) and L
large). The S RNA encodes major structural proteins. It
ontains a nucleoprotein (NP) gene at the 39 end in a
egative polarity and a GPC gene coding for precursor of
iral glycoproteins (GP1 and GP2) at the 59 end in a
essage-sense polarity (Southern et al., 1987). Similarly,
he L RNA encodes RNA-dependent RNA polymerase (L)
nd zinc-binding protein with proposed regulatory func-
ion (Z) in a mutually opposite orientation (Salvato and
himomaye, 1989). This unusual ambisense arrange-
ent may contribute to viral persistence, frequently es-
ablished by arenaviruses, by allowing independent reg-
lation of viral protein synthesis and virion production.
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 1421 7 5477 4284. E-mail: virupast@savba.sk.
73LCMV is classified as an Old World arenavirus (Buch-
eier et al., 1995). It is maintained in nature by lifelong
ersistence in wild mice, but is transmissible to diverse
ammalian hosts, including human. The primary route of
nfection is via contact with mice secretions. Human
nfections are usually subclinical or mild and in a minor-
ty of cases result in severe or lethal meningoencepha-
itis. There are also some reports of transplacental infec-
ion causing fetal abortion or malformation. Human
ases of LCMV infection are characterized by a rise in
ntibody titer followed by lasting immunity (Ja¨hrling and
eters, 1992, Peters et al., 1996).
LCMV grows in a wide variety of cells and is usually not
ytolytic. After an initial period of active viral replication, the
ells progress toward a state of persistent infection with
ignificantly reduced viral replication and limited accumu-
ation of viral glycoproteins at the cell surface (Oldstone and
uchmeier, 1982; Bruns et al., 1990). The cytoplasm of
nfected cells contains high levels of nucleoprotein and
enomic, subgenomic, and truncated forms of viral RNAs
Francis and Southern, 1988). LCMV persistent infection in
itro is frequently, but not necessarily, connected with gen-
ration of defective interfering particles (Martı´nez Peralta et
l., 1981; van der Zeijst, 1983a). A novel mode of both in vivo
nd in vitro persistence of LCMV-specific sequences in a
NA form was proposed recently by Klenerman et al.
1997).
A number of cell lines not intentionally inoculated with
0042-6822/99 $30.00
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74 REISEROVA´ ET AL.FIG. 1. Sequence comparison of MX LCMV nucleoprotein. Alignment of NP amino acid sequences of the following Old World arenaviruses (with
elevant GenBank accession numbers): LCMV strains MX (Y16308), Armstrong (ARM, M20869), and WE (M22138); Lassa fever virus strains GA 391
GA, X52400) and Josiah (LA, J04324); and Mopeia virus (MO, M33879). Black blocks indicate the conservative amino acids. Positions of the tryptic
eptides generated from purified MX NP and subjected to sequencing are designated by dots above the corresponding amino acid residues.
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75MaTu-MX AGENT IS A NEW STRAIN OF LCMVCMV were found to be persistently infected with this virus,
robably as a result of passage through infected hamsters
r mice (van der Zeijst et al., 1983a). Here we provide an
dditional example of carcinoma cell line MaTu presumably
erived from human mammary tumor (Widmaier et al., 1974)
nd grown in a mixed culture with HeLa cells (Za´vada et al.,
972; Za´vada, 1993). We demonstrate that a transmissible
gent, MaTu (Za´vada et al., 1974), is LCMV and that MaTu-
erived antigen is in fact a viral nucleoprotein.
Identity of the MaTu agent has remained obscure for
any years due to its seemingly extraordinary proper-
ies: it is noncytolytic, does not cause transformation or
emagglutination, and no virus particles were seen by
lectron microscopy. Its only biological manifestation
as the capacity to form pseudotypes with vesicular
tomatitis virus (VSV). MaTu was transmissible only by
ell-to-cell contact, not by filtered media from infected
ells. The host range of he MaTu agent appeared to be
estricted to HeLa and HEF cells. It was not transmissi-
le to human tumor cell lines T24, T47D, and HMB2 or to
arious animal cell cultures. Paradoxically, some human
nd animal sera contained MaTu-specific antibodies that
recipitated from MaTu cell extract a single protein of 58
Da (Za´vada and Za´vadova´, 1991).
Monoclonal antibodies raised against MaTu cells al-
owed discrimination of two different proteins involved in
he MaTu phenomenon (Pastorekova´ et al., 1992). An
ndogenous cellular protein, MN, localized at the plasma
embrane and participating in formation of VSV pseudo-
ypes has become a subject of intense investigations
ue to its strong association with human carcinomas
Pastorek et al., 1994). An exogenous, transmissible
gent, MX, is related to a 58-kDa protein localized in the
ytoplasm and precipitated by human and animal sera.
In this paper, we describe the purification, cloning, and
dentification of this protein as a nucleoprotein of LCMV.
ccording to sequencing data we propose that MX rep-
esents a novel strain of LCMV. Using MX-LCMV nucleo-
rotein extracted from MaTu cells we show a relatively
FIG. 2. Northern blotting analysis of MX LCMV RNA with the NP
DNA probe of LCMV strain Armstrong. Northern blot of 10 mg of total
NA isolated from MX LCMV-infected MaTu cells (M) and uninfected
eLa cells (H) was hybridized with 32P-labeled double-stranded NP
DNA probe derived from LCMV strain Armstrong and analyzed by
autoradiography.igh prevalence of anti-LCMV antibodies in human sera,
uggesting the possibility of horizontal human-to-human
ransmission of the LCM virus.
RESULTS
mino acid sequence analysis revealed MaTu-MX
gent as LCMV
To elucidate the molecular character of the MaTu-MX
FIG. 3. Comparative immunoprecipitation of MX LCMV and WE
CMV nucleoproteins. Cell extracts from control HeLa (H), MX LCMV-
nfected MaTu (M), and WE LCMV-infected HeLa (W) were immunopre-
ipitated with (lanes 1) human KH serum from mammary carcinoma
atient, (2) human serum from healthy donor, (3) sheep anti-VSV serum,
4) sheep anti-HeLa serum, (5) rabbit anti-LCMV serum, (6) rabbit
nti-MaTu serum, (7) normal rabbit serum, and (8) M16 monoclonal
ntibody specific for the MX NP. Immune complexes were bound to S.
ureus cells, subjected to SDS–PAGE, and analyzed by autordiography.gent, we have purified MX-related 58-kDa protein by
i
M
p
t
s
q
p
a
t
f
t
I
i
t
H
N
i
L
L
c
c
y
T
m
s
s
g
v
R
t
L
e
c
B
m
p
w
m
s
a
s
t
i
p
b
e
p
O
p
t
t
m
l
a
c
s
t
m
c
e
h
8
s
s
m
f
t
Y
r
t
h
a
s
s
s
h
A
M
N
a
i
q
q
v
c
t
s
t
r
t
M
I
a
(
o
a
p
f
c
C
76 REISEROVA´ ET AL.mmunoprecipitation with specific monoclonal antibody
16 followed by electroelution from SDS–PAGE. Purified
rotein was subjected to trypsin digestion and four tryp-
ic fragments were analyzed by amino-terminal protein
equencing. Comparison of partial amino acid se-
uences with the protein databases revealed that MX
rotein is closely related to NP of LCMV (Fig. 1). The
mino acid sequences of three fragments were identical
o the NP sequence of WE strain LCMV. However, the
ragment corresponding to amino acids 116–134 con-
ained three changes at positions 116, 121, and 131.
nterestingly, two substitutions are localized within an NP
mmunodominant epitope involved in recognition by an-
iviral cytotoxic T cells in mice of the H-2d, H-2u, and
-2q haplotypes (Oldstone et al., 1992).
orthern blot hybridization and comparative
mmunoprecipitation
Northern blotting analysis confirmed the presence of
CMV RNA in MaTu cells. NP cDNA probe derived from
CMV strain Armstrong hybridized under high-stringency
onditions to RNA isolated from MaTu cells, but not from
ontrol uninfected HeLa cells (Fig. 2). The hybridization
ielded two major bands of 1.6 and 2.4 kb, respectively.
he smaller band corresponded to NP mRNA. The larger,
ore abundant band belonged to a molecule that was
maller than genome-sized, but larger than messenger-
ized RNA and most probably represented either sub-
enomic S RNA or deleted genomic S RNA. The third
ery faint band was at the position of the full-length S
NA. Molecules of similar size and pattern were de-
ected before in mouse L cells persistently infected with
CMV strain Armstrong (Bruns et al., 1990). Van der Zeijst
t al. (1983b) also found that most of the RNA that
oprecipitated with LCMV NP from persistently infected
HK cells was smaller than the standard LCMV RNAs.
In addition, comparative immunoprecipitation experi-
ents have shown cross-reactivity between the nucleo-
rotein of LCMV strain WE and MX protein. Both proteins
ere precipitated from extracts of infected cells by com-
ercial rabbit anti-LCMV serum, by rabbit anti-MaTu
erum, by monoclonal antibody M16 raised against MX,
s well as by human KH serum (anti-MaTu) and by
everal animal sera (Fig. 3). Efficiency of immunoprecipi-
ation differed for different serum/antigen combinations,
ndicating that antigenic properties of the two compared
roteins are related, but not the same. Monoclonal anti-
ody M16 precipitated MX protein with a much higher
fficiency than NP of WE LCMV. Also four of five positive
olyclonal sera reacted more strongly with MX protein.
nly the rabbit anti-LCMV serum was equally efficient in
recipitation of both proteins. Furthermore, mobility of
he proteins in SDS–PAGE differed slightly, suggesting
hat they are very similar, but not identical. The molecularass of MX NP (58 kDa) corresponded well to the mo- cecular mass of LCMV NP described by van der Zeijst et
l. (1983b) in persistently infected BKH cells.
DNA sequence of MX nucleoprotein
Based on these results, we have decided to clone and
equence a cDNA encoding the MX-LCMV nucleopro-
ein. For this purpose, we have employed an RT-PCR
ethod using primers designed according to sequences
onserved among known LCMV NP genes. Because the
xpected size of the whole cDNA was relatively large, we
ave amplified three overlapping cDNA fragments of 584,
29, and 475 nt. The fragments were cloned into pBlue-
cript and at least two clones of each fragment were
equenced from both sides with NP-specific and plas-
id-derived primers. No sequence differences were
ound among the corresponding clones as expected on
he basis of employment of Pfu polymerase RT PCR.
The compiled cDNA sequence (EMBL Accession No.
16308) was 1722 nt long. It contained a single open
eading frame starting with ATG at position 46–48 and
erminating with UAA at position 1720–1722. The ORF
ad a coding capacity for a 558-amino-acid protein with
predicted molecular mass of 62.2 K. The nucleotide
equence comparison of MX with LCMV strains Arm-
trong and WE revealed 85.1 and 86.5% homology, re-
pectively. These values were close to 85.1% sequence
omology of the relevant regions between the strains
rmstrong and WE. Deduced amino acid sequence of
X NP showed 23 amino acid changes in comparison to
P of the strain Armstrong (95.5% identity) and 27 amino
cid changes compared to NP of the strain WE (94.6%
dentity). Mutual Armstrong and WE NP amino acid se-
uence identity was similar, i.e., 95.7%. Amino acid se-
uence identity of MX LCMV with other Old World Arena-
iruses, namely Lassa (62%) and Mopeia (65.4%), was
onsiderably lower. Five of the amino acid changes de-
ected in MX NP sequence are at the positions con-
erved among all aligned arenavirus NP sequences, but
heir biological significance remains unknown (Fig. 1).
The above data indicate that MX LCMV is as equally
elated to both LCMV strains Armstrong and WE, as
hese two strains are one to another and suggest that
X is a separate strain of LCMV.
nfectious properties of MX-LCMV
In the previous studies it was proposed that MaTu-MX
gent, i.e. MX-LCMV, had a strictly human host range
Za´vada and Za´vadova´, 1991). This proposal was based
n attempts to transmit the virus to different human and
nimal cell lines in vitro. The only cell lines found to be
ermissive for the MX-LCMV were HeLa, human embryo
ibroblasts (HEF), and HeLa 3 fibroblast hybrids. These
ells became infected via direct contact with mitomycin
-treated MaTu cells. Spread of the virus in the recipient
ells was very slow as detected by immunoprecipitation
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77MaTu-MX AGENT IS A NEW STRAIN OF LCMVZa´vada et al., 1993). The virus was not transmissible by
iltered medium from infected cultures (Za´vada et al.,
972, 1974).
It is well documented that LCM virus can infect differ-
nt cell types of various mammalian species. From this
oint of view, the restricted host range of MX-LCMV
ppeared to be rather exceptional. To prove this special
roperty of MX-LCMV, we have performed series of
ocultivation experiments with MaTu cells as a donor of
X-LCMV. Following the procedure of van der Zeijst et al.
1983a), we have also used cell-free extracts of MaTu
ells for virus transfer. The recipient cells included HeLa
as a positive control for monitoring the transmission).
GS, Vero, MDCK, NIH 3T3, and CHO cells. As before,
e have transmitted MX-LCMV to HeLa cells by coculti-
ation (Figs. 4b and 4c) as well as by cell-free extract of
aTu cells (not shown). Moreover, we have succeeded
n infecting Vero monkey kidney cells (Figs. 4d–4f) by
oth methods. In recipient HeLa cells, MX NP antigen
as detectable 7 days postinfection (just after the first
assage). At this point, only few infected cell clusters
illed with MX NP were dispersed in otherwise negative
ulture. During the next two passages, virus spread to
ore cells (Fig. 4b). Finally, most cells in culture were
ound to contain MX at passage 4 (Fig. 4c). Infection in
ero cells proceeded more slowly. The first signs of
nfection were apparent between passages 2 and 3
Figs. 4d and 4e). The infection process was completed
t passage 9, 2 months from the beginning of the exper-
ment (Fig. 4f). In accord with observations of other au-
hors, newly infected cells (both HeLa and Vero) did not
how any cytopathic effect.
However, we were repeatedly unable to transmit
nd/or spread the virus in AGS, MDCK, CHO, and NIH
T3 cells by either of two means. Only very few MX NP
ntigen-positive cells could be detected in NIH 3T3 and
HO populations from passages 4 to 8 after the trans-
ission (Fig. 4g), but they disappeared during the follow-
ng passages. No MX NP antigen could be found in AGS
r MDCK cells during the period of 2 months (Fig. 4h).
hese results support the view that the in vitro host
ange of MX-LCMV is restricted to certain primate cells.
hey also indicate that the virus transmission to an
ninfected cell population on one hand, and its mainte-
ance and spread within this population on the other
and require two independent sets of cellular factors.
ulse–chase analysis of MX NP intracellular stability
Cells persistently infected by LCMV were shown here
nd elsewhere (Welsh and Buchmeier, 1972; van der
eijst et al., 1983b; Bruns et al., 1990) to contain a lot of
ytoplasmic nucleoprotein. We have performed [35S]me-
hionine pulse-labeling of MaTu cells, followed by differ-
nt chase intervals and immunoprecipitation with M16
onoclonal antibody to see whether a large amount of untracellular NP was due to the rate of its synthesis or to
ts stability. As shown in Fig. 5a, MX NP was easily
etectable after a 5-min pulse in MaTu extract containing
0 mg of total proteins and its level was stable during the
ubsequent 5 days of chase. A small amount of MX NP
as detectable also in culture medium (Fig. 5b), most
robably as a result of release from dead cells. On the
asis of the data obtained we propose that MX NP is
ccumulated in persistently infected MaTu cells as a
esult of both its high rate of synthesis and high intra-
ellular stability.
mployment of MX NP as an antigen for detection of
nti-LCMV antibodies in human sera
As found before by Za´vada and Za´vadova´ (1991) sev-
ral human sera contained antibodies that precipitated
he so-called MaTu antigen of 58 kDa (now known to be
he NP of MX LCMV) from the extract of MaTu cells. In
ddition, comparative immunoprecipitation described in
his paper has shown that human and animal sera re-
cted more strongly with MX NP than with NP of LCMV
train WE. These findings prompted us to employ MX NP
xtracted from MaTu cells, as an antigen for detection of
nti-LCMV antibodies in human sera by immunoprecipi-
ation. We have analyzed 56 serum specimens collected
t the regional hygienic station in Bratislava, Slovakia
nd found that 37.5% of the samples were clearly positive
Fig. 6a). Specificity of the results was confirmed both
sing extract from uninfected HeLa cells as a negative
ontrol and employing monoclonal antibody M16 in com-
etitive immunoprecipitation with human sera (data not
hown).
To prove the above data and obtain a quantitative
etermination of LCMV NP-specific antibodies in human
era, we have developed an immunoprecipitation-related
olid-phase radioimmunoassay (SP-RIA) based on utility
f anti-NP monoclonal antibody M67 as a specific detec-
or. We have used Staphylococcus aureus cells contain-
ng protein A (PA) to coat wells of microtiter plates. After
ddition of human serum, the PA selectively bound IgG
olecules through their Fc ends and directed their Fab
ermini with the binding sites toward the antigen present
n MaTu cell extract added in the next step. The amount
f MX NP captured by human antibodies was then de-
ermined by iodinated MAb M67 having diminished
ross-reactivity to PA due to the IgG1 isotype. The anal-
sis of all serum samples revealed data corresponding
o results of the immunoprecipitation (Fig. 6b).
The average age of 56 individuals whose sera were
nalyzed was 40.7 years (ranging from 16 to 69). The
verage age of seropositive persons was 44.9 years; 30%
f the individuals were younger than 30 years. They were
rom Bratislava City or its surroundings and no apparent
elationships were found among the seropositive individ-
als.
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78 REISEROVA´ ET AL.The 37.5% anti-LCMV antibody prevalence in human
era is considerably higher than the values reported
efore, e.g., 9.1% found in rural residents in the north of
ermany (Ackerman, 1973), 5% detected in the inner city
FIG. 4. Immunofluorescence analysis of MX LCMV transmission by
ninfected HeLa cells, (b) HeLa cocultivated with MaTu, 2nd passage
aTu, 3rd passage, (f) Vero 1 MaTu, 9th passage, (g) CHO 1 MaTu, 8t
nd analyzed for presence of MX NP using M16 monoclonal antibody a
003 (d–f).f Birmingham (Stephensen et al., 1992; Park et al., 1997), bnd 4–10% in some localities in Argentina (Ambrosio et
l., 1994). The difference was probably due to both the
igher sensitivity of our detection systems compared to
he previously used methods and determination of anti-
vation of donor MaTu cells (i) with different recipient cells: (a) control
La 1 MaTu, 4th passage, (d) Vero 1 MaTu, 2nd passage, (e) Vero 1
age, (h) MDCK 1 MaTu, 10th passage. Cells were fixed with methanol
-conjugated secondary antibodies. Magnification 4003 (a–c, g–i) andcoculti
, (c) He
h pass
nd FITCodies specific to viral nucleoprotein. This might be
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79MaTu-MX AGENT IS A NEW STRAIN OF LCMVmportant in view of a decreased production of viral
lycoproteins during persistent infection (Oldstone and
uchmeier, 1982), potentially resulting in a diminished
nti-GP humoral response compared to that against NP.
he tests presented here, of course, did not reveal the
CMV strain-specificity of the antibodies. Nevertheless,
he fact that as many as 37.5% of the inhabitants of the
ratislava area that were tested had antibodies to LCMV
uggests that rodents might not be the only source of
CMV infection and indicates that the virus could be
otentially spread throughout the human population by
uman-to-human transmission. However, to confirm this
ypothesis, data from a larger number of individuals will
e required. This will be made possible by the availability
f the assay described in this study.
DISCUSSION
LCMV can easily induce persistent infection in a broad
ange of cells derived from various species. Since the
irus is usually maintained without any apparent signs of
ytopathic effect, the infection might remain unrecog-
ized. This was the case for the human carcinoma cell
ine MaTu that was found to contain a transmissible
gent, MX, whose nature, however, was not elucidated
or quite a long time. Here we show that this agent is
CMV.
Looking back at the biological features of the MaTu-MX
gent, we can see several similarities with persisting
CMV. These are lack of distinct virions, noninfectious
ulture fluid, absence of cellular damage, transmission
y cell-to-cell contact, accumulation of cytoplasmic nu-
leoprotein of 58 kDa, the presence of deleted RNAs,
nd reactivity with human sera and sera of experimental
nimals (van der Zeijst et al., 1983a, 1983b; Francis and
outhern, 1988; Bruns et al., 1990).
However, apparent restriction of MX host range to
uman cells HeLa and HEF had complicated the recog-
ition of the identity of MX. In this work, we succeeded in
nfecting by MX LCMV the Vero monkey kidney cells, but
ur attempts to transmit the virus to AGS, MDCK, NIH
T3, and CHO cells failed. The period from initial contact
f recipient cells with MX LCMV-infected MaTu cells or
ith their homogenate to first detection of MX LCMV NP
ncreased from 7 days in HeLa cells to 14 days in Vero
ells.
In contrast, LCMV from persistently infected BHK ham-
ter cells studied by van der Zeijst et al. (1983a) was
ransferable to human, monkey, rat, hamster, and mouse
mbryo cells. Infection of hamster and rat cells was
pparent 6–7 days after transmission, while infection of
uman and monkey cells was very slow, being detect-
ble within approximately 10–24 days. Moreover, cells
erived from bovine kidney, chick embryo, rat hepatoma,
nd most mouse cells tested were resistant to infection
y LCMV from BHK cells. pIt is possible that in both cases of persistent LCMV
nfection (i.e., in HeLa and in BHK cells), the viruses
nderwent an adaptation to the cellular environment,
esulting in certain restriction of their host range in vitro.
his adaptation could be accomplished by selection of
irus variants present within LCMV populations and
ompeting for cellular factors facilitating virus replication
nd spread. LCMV variants with different phenotypic
roperties, including altered tissue tropism and pathol-
gy in vivo, were described (Dutko and Oldstone, 1983;
hmed et al., 1991; Buesa-Gomez et al., 1996; Teng et al.,
996). The phenotypic alterations were shown to be
ssociated with a single mutation or only a few amino
cid changes in the viral GP or NP (Teng et al., 1996;
hmed et al., 1991). The study of Bruns et al. (1990)
uggests that LCM virus with an altered phenotype can
e also obtained in vitro upon conditions of persistent
nfection.
However, our sequencing data on MX NP indicate that
X LCMV did not arise just as a result of in vitro adap-
ation of standard LCMV. Since the mutual cDNA homol-
gy between LCMV strains WE and Armstrong is as high
s that between either MX and WE or MX and Armstrong,
e assume that MX is in fact a novel LCMV strain. This
iew is in accord with data obtained recently by compar-
tive analysis of MX LCMV Z cDNA sequence (Gibadu-
inova´ et al., 1998). Nevertheless, to provide convincing
vidence supporting our assumption, further studies of
he biological properties of this virus are needed.
Despite the lack of detailed knowledge of MX LCMV,
tility of MX NP in detection of anti-LCMV antibodies in
uman sera by immunoprecipitation revealed important
ata. We found that the antibody prevalence of 37.5% in
ested samples from the population of Bratislava, Slova-
ia, is much higher than that described previously for the
ifferent regions in the United States, Germany, or Ar-
entina (Ackerman, 1973; Stephensen et al., 1992; Am-
rosio et al., 1994; Park et al., 1997). It is generally
ccepted that human infection of LCMV occurs via the
espiratory tract after contact with excreta of infected
odents and that interhuman transmission is rare. More-
ver, human disease produced by LCMV does not ap-
ear to be of considerable public health importance,
lthough several authors warn that the significance of
he virus might be underestimated (Lehmann-Grube and
mbrassant, 1977; Oldstone, 1989; Ja¨hrling and Peters,
992; Stephensen et al., 1995). Our data suggest that
CMV may be more widely distributed than has been
reviously thought and indicate the possibility of horizon-
al spread of LCMV in the human population. At the same
ime, they strengthen the importance of questions about
ossible involvement of this virus in human diseases.
here is evidence that persistent LCMV infections could
mpair specialized cellular functions without apparent
ell pathology, suppress immune functions in vivo, or
erturb homeostatic mechanisms of a host organism
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80 REISEROVA´ ET AL.Oldstone et al., 1982, 1984; Saron et al., 1990; de la Torre
nd Oldstone, 1992). Thus, it is not inconceivable that
his virus might “silently” contribute to disease develop-
ent in humans. Therefore, a larger standardized
creening of prevalence of LCMV antibodies in the gen-
ral human population as well as in selected groups of
atients with diseases of unknown etiology is necessary
or understanding the mode of spread and possible in-
olvement of LCMV.
MATERIALS AND METHODS
ell lines, sera, and monoclonal antibodies
Human MaTu cells (described in Za´vada and Za´va-
ova´, 1991). HeLa cervical carcinoma cells, AGS human
astric adenocarcinoma cells, Vero monkey kidney cells,
DCK canine kidney cells, NIH 3T3 mouse fibroblasts,
nd CHO hamster ovary cells were maintained in Dul-
ecco’s MEM (BioWhittaker) supplemented with 10%
eat-inactivated fetal calf serum (Gibco BRL) and 40
g/ml gentamicine (LEK, Slovenia).
KH serum from mammary carcinoma patient and rab-
it anti-MaTu serum were as previously described (Za´-
ada et al., 1972, Za´vada and Za´vadova´, 1991). Human
era were provided by Dr. Sˇimkovicˇova´ (Regional Hy-
enic Station, Bratislava) and Dr. Pru¨merova´ (Clinics of
ematology and Transfusiology, Bratislava). Rabbit anti-
CMV serum was from Imuna Sˇarisˇske´ Michal’any (Slo-
akia). Other animal sera were as used previously (Za´-
ada and Za´vadova´, 1991).
Monoclonal antibodies M16 (IgG2a isotype) and
67 (IgG1 isotype) specific to LCMV nucleoprotein
ere prepared against the 58-kDa protein precipitated
rom MaTu cell extract by rabbit anti-MaTu serum
FIG. 5. Pulse–chase analysis of MX LCMV NP in MaTu cells (a) and
n culture medium (b). MaTu cells were pulse-labeled with [35S]methi-
nine for 5 min. Cell extracts and culture media were collected after
ifferent chase intervals (1) 24 h, (2) 48 h, (3) 72 h, (4) 96 h, and (5) 120 h
nd subjected to immunoprecipitation with M16 monoclonal antibody.
he immunoprecipitated proteins were analyzed by PAGE and autora-
iography.Pastorekova´ et al., 1992). M16 was purified from hy- pridoma medium by affinity chromatography using
rotein A–Sepharose (Pharmacia); M67 was purified
rom ascites fluid by caprylic acid according to Mc-
inney and Parkinson (1987) and iodinated by the
hloramine T method (Hunter, 1978).
iruses
MX-LCMV (originally called MaTu agent) was main-
ained as a persistent virus in MaTu cells (Za´vada and
a´vadova´, 1991; Pastorekova´ et al., 1992).
The standard WE strain of LCMV was kindly provided by
rofessor Chastel (Faculty of Medicine, Brest, France).
irus was passaged through a rat brain and propagated
n Vero clone E6 cell line. Titer of virus was determined
y plaque assay on Vero E6 cells.
nfection of HeLa cells by WE LCMV
HeLa cells were seeded at a concentration of 5 3 105
ells per 6-cm petri dish 20 h before infection. The cell
FIG. 6. Analysis of LCMV-specific antibodies in human sera by
mmunoprecipitation (a) and solid-phase radioimmunoassay (b) us-
ng MX NP as an antigen. (a) Extracts of MaTu cells were allowed to
eact with human sera (lanes 1–11) and M16 monoclonal antibody
lane 12). Immune complexes were bound to S. aureus cells, sub-
ected to PAGE and analyzed by autoradiography. (b) Human sera
ere bound to wells coated by S. aureus cells with PA and allowed
o react with NP in MaTu cell extract. Captured NP was detected by
25I-labeled M67. The amount of NP-specific human antibodies in
ndividual serum specimens was expressed as cpm of bound M67
er well.
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81MaTu-MX AGENT IS A NEW STRAIN OF LCMVonolayers were infected with WE LCMV at m.o.i. 0.1.
fter 1 h of virus adsorption at 37°C, the inoculum was
emoved. The cells were washed to get rid of nonadher-
nt virus and finally, fresh medium was added. Infected
ells were harvested after 48 h and lysed with RIPA
uffer as described below. Cell lysate was used as a
ource of viral proteins for comparative immunoprecipi-
ation.
X-LCMV transmission by cocultivation and by
noculation with cell-free extracts
Before cocultivation, 1 3 106 donor MaTu cells were
ncubated with 5 mg/ml mitomycin C (Sigma) for 16 h.
reated cells were trypsinized and divided into two parts.
he first part was plated for control of complete death of
onor cells. The second part corresponding to 5 3 105
aTu cells was mixed with the same number of unin-
ected recipient cells and seeded onto a petri dish of 6
m in diameter. Mixed cultures were subcultured after
–5 days and then one or two times per week. Alterna-
ively, cell-free extracts were prepared from MaTu cells
y the procedure of van der Zeijst et al. (1983a). Cells for
nfection were plated at low density 16 h before use.
hen the MX-LCMV in cell-free extracts was allowed to
dhere to PBS-washed cells for 1 h at room temperature.
inally, the virus inoculum was removed and fresh me-
ium was added. The cells were cultivated as described
bove. Spread of infection was followed by immunofluo-
escence detection of MX-LCMV nucleoprotein in recip-
ent cells.
mmunofluorescence
Cells grown on glass coverslips were fixed with meth-
nol at 220°C for 5 min, washed with PBS, incubated for
0 min in PBS containing 1% BSA, and treated for 1 h at
7°C with the monoclonal antibody M16 in hybridoma
edium. After washing, FITC-conjugated swine anti-
ouse secondary antibodies (Sigma) were added for 1 h.
hen the samples were washed with PBS, mounted in
nti-bleach medium (PBS containing glycerol, formalde-
yde, and citifluor at a ratio of 9:1:1), and examined under
Nikon fluorescence microscope.
adioimmunoprecipitation
Cells were labeled overnight by 10 mCi/ml [35S]methi-
nine (Amersham) in methionine-free MEM supple-
ented with 2% FCS and 3% complete MEM. Alterna-
ively, the methionine-starved cells were pulse-labeled
or 5 min by 50 mCi/ml [35S]methionine and chased for
ifferent time periods. Protein extracts were prepared by
ysis of the labeled cells with RIPA buffer (140 mM NaCl,
.5 mM phosphate buffer, pH 7.2, 1% Triton X-100, 0.1%
eoxycholate, 1 mM PMSF, and Trasylol) for 3 min at 4°C.
o minimize nonspecific precipitations, extracts were
leared by centrifugation at 14,000 rpm for 15 min and rreadsorbed with a suspension of formalin-fixed S. au-
eus cells (SAC) containing Protein A. Following pread-
orption, extracts were incubated for 1 h at 4°C with sera
r monoclonal antibody. Then the SAC were added to
recipitate the immune complexes. The precipitates
ere washed and analyzed by 10% SDS–PAGE. Precipi-
ated proteins were visualized by fluorography.
etermination of LCMV NP-specific antibodies in
uman sera by solid-phase radioimmunoassay
SP-RIA)
PVC microtiter plates were coated overnight at 37°C
ith 50 ml/well of 0.25% suspension in PBS of heat-killed
ormalin-fixed S. aureus cells with protein A (PA). After
ried cells were washed with PBS, 50 ml/well of the
uman sera diluted 1:20 in PBS was added and allowed
o react overnight at 4°C. All subsequent steps were
erformed at room temperature and followed by exten-
ive washing with PBS 1 1% FCS. The wells were sat-
rated with 200 ml of PBS containing 10% FCS for 2 h.
aTu cell extract (50 ml/well) diluted 1:20 in PBS 1 1%
CS (corresponding to 10 mg of total proteins) was added
nd allowed to react for 2 h. Finally, 50 ml/well (about
0,000 cpm) of 125I-labeled M67 was added and incu-
ated for 1 h. The amount of labeled M67 bound per well
as measured in a CliniGamma 1272 (LKB) counter.
onspecific binding of M67 to PA was tested in the same
P-RIA, omitting either human serum or both human
erum and MaTu cell extract, and was found to be
nsignificant.
urification and sequencing of MX-specific 58-kDa
rotein
MX-specific protein was precipitated from MaTu ex-
ract by monoclonal antibody M16 and SAC and sub-
ected to 10% SDS–PAGE. Gel was stained by 0.5% Coo-
assie brilliant blue in 10% acetic acid and 30% isopro-
anol. The stained protein band was excised from the
el and cut into small pieces. The gel fragments were
oaked in blotting buffer (Laemmli’s electrode buffer di-
uted 1:10 in H2O, without methanol) containing 2% SDS
or 3 h at room temperature. Then the blotting buffer with
.1% SDS was layered over the soaked gel placed in an
lution chamber of an electroelution apparatus. The pro-
ein was electroeluted overnight at 50 V, precipitated with
mixture of methanol and acetone (1:1) at 220°C and
issolved in buffer containing 20 mM Tris–HCl, pH 8, 150
M NaCl, 0.1% SDS, and 1 mM PMSF.
Purified protein was digested with trypsin and the
eptides generated were purified by high-performance
iquid chromatography. Tryptic peptides were subjected
o N-terminal amino acid sequencing using a Model
73A Protein Sequencer (Applied Biosystems Ltd., War-
ington, UK).
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82 REISEROVA´ ET AL.CR amplification, cloning, and sequencing
f MX-LCMV nucleoprotein cDNA
Three overlapping fragments covering the entire nu-
leoprotein gene were produced by reverse transcrip-
ase-polymerase chain reaction (RT-PCR). One micro-
ram of total RNA isolated from MaTu cells (Chomczyn-
ki and Sacchi, 1987) was primed in separate reactions
ith the relevant antisense oligonucleotide and tran-
cribed with the SuperScript reverse transcriptase
Gibco BRL). One-twentieth of single-stranded cDNA was
mplified in Gene ATAQ Controller (Pharmacia) in a 25-ml
eaction buffer volume containing 0.2 mM each of the
our dNTPs and a 0.2 mM concentration of each primer.
fu DNA polymerase (0.625 m; Stratagene) was added at
5°C. Primer pairs and reaction profiles were used as
escribed below. The primers were designed according
o WE and Armstrong LCMV sequences (GenBank Ac-
ession Nos. M22138 and M20869); numbers in paren-
heses show positions with respect to WE S RNA. PCR 1:
9-ATTGAATTCACAGTGGATCCTAGGCATTTGATT-39 (3372–
349) and 59-GGCATTGTGCCRAAYTGATTGTTC-39 (2789–
812), 40 cycles (40 s at 94°C, 40 s at 60°C, and 75 s at
2°C). PCR 2: 59-GTGCAAGTGGTGTRGTAAGRGTTT-39
2861–2838) and 59-AAGATCCATGCCGTGTGARTACTT-39
2032–2055), 40 cycles (40 s at 94°C, 40 s at 64°C, and
0 s at 72°C). PCR 3: 59-GGCARTTCATACAYTTTTACAGR-
AA-39 (2114–2089) and 59-TTAGAGTGTCACAACATT-
GGTCCT-39 (1639–1663), 40 cycles (30 s at 94°C, 40 s
t 62°C, and 60 s at 72°C). Three PCR products of
xpected sizes were agarose gel-purified and subcloned
nto EcoRV-digested pBluescript. Double-stranded DNA
rom recombinant clones was sequenced with the T7
equencing kit (Pharmacia). Sequence data were sub-
itted to the EMBL database and have been assigned
ccession No. Y16308.
orthern blot analysis
Ten micrograms of total RNA from MaTu cells and from
ninfected HeLa cells was separated on 1% agarose–
ormaldehyde gel and transferred to Hybond-C super
embrane (Amersham) by capillary blotting. The mem-
rane was probed with LCMV strain Armstrong nucleo-
rotein cDNA excised by BglII from pSV2B plasmid that
as kindly provided by Dr. Peter Southern, University of
innesota, Minneapolis (Oldstone et al., 1991). The
robe was labeled with [a-32P]dCTP using the Mega-
rime DNA Labeling System (Amersham). Prehybridiza-
ion, hybridization, and washing under stringent condi-
ions were performed according to Sambrook et al.
1989). Northern blot was analyzed by autoradiography.
NA sizes were estimated using a 0.24- to 9.5-kb RNAadder (Gibco BRL). OACKNOWLEDGMENTS
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